


Chart 1: Data from the NOVA Study with Niraparib



1. Mirza MR, Monk, BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum Sensitive, Recurrent Ovarian Cancer. *N Engl J Med*. Oct. 8, 2016.
Notes: gBRCA+ = germline *BRCA1/2* mutation positive, gBRCA- = germline *BRCA1/2* mutation negative, HRD+ = homologous recombination deficient positive, HRD- = homologous recombination deficient negative.